| Bioactivity | SH1573 is an orally active mIDH2 inhibitor. SH1573 has a strong and selective inhibitory effect on mIDH2 R140Q protein (IC50=4.78 nmol/L), and can effectively reduce the production of the carcinogenic metabolite 2-hydroxyglutarate (2-HG) in animal models, cell lines, serum and tumors. SH1573 can be used for the study of acute myeloid leukemia (AML)[1]. |
| CAS | 2376068-96-9 |
| Formula | C21H18F9N7O4S |
| Molar Mass | 635.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhiqiang Wang, et al. "Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China." Acta Pharmaceutica Sinica B 11.6 (2021): 1526-1540. |
SH1573
CAS: 2376068-96-9 F: C21H18F9N7O4S W: 635.46
SH1573 is an orally active mIDH2 inhibitor. SH1573 has a strong and selective inhibitory effect on mIDH2 R140Q protein (
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.